The management of cytomegalovirus (CMV) infection was assessed with a survey performed in 2020 by the Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation (EBMT). One-hundred-eighty of the 579 EBMT centres (31%) responded. CMV monitoring with quantitative PCR for CMV-DNAemia was used by 97% of centres while...
-
2023 (v1)PublicationUploaded on: February 14, 2024
-
2021 (v1)Publication
Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use...
Uploaded on: February 14, 2024 -
2022 (v1)Publication
Nocardiosis is a late post-hematopoietic cell transplantation (-HCT) infection usually manifesting as pulmonary disease with frequent dissemination, brain infection, and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.Background Nocardiosis is rare...
Uploaded on: February 14, 2024